Centessa Pharmaceuticals PLC
CNTA
$9.40
Closing
▼-6.00%
1D
▲18.09%
YTD
Market cap
$942.87M
52 week high
$12.40
52 week low
$4.10
Volume
35,040
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$942.87M
Analysts' Rating
BUY
Price Target (Mean)
11
Total Analysts
6
P/E
Operating Margin
0.00%
Beta
Revenue Growth (Annual)
0.00%
52 week high
$12.40
52 week low
$4.10
Div. Yield
%
EPS Annual Growth
53.85
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company’s advanced product candidate, SerpinPC, is a subcutaneously administered inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia. Leveraging its LockBody technology, it is developing an approach to selectively drive potent effector function activity, such as CD47 or CD3, into the tumor microenvironment (TME) while avoiding systemic toxicity. Its first LockBody product candidate, LB101, is a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody used in solid tumors. Its other programs consist of earlier-stage preclinical assets, including ORX750, an orally administered, selective Orexin Receptor-2 (OX2R) agonist for the treatment of narcolepsy (NT1) with potential expansion into other sleep disorders, and MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH).
